Middle East African Journal of Ophthalmology

DIABETIC RETINOPATHY UPDATE
Year
: 2015  |  Volume : 22  |  Issue : 2  |  Page : 164--173

Novel pharmacotherapies in diabetic retinopathy


Vaidehi S Dedania1, Sophie J Bakri2 
1 Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY 12208, USA
2 Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905, USA

Correspondence Address:
Sophie J Bakri
Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905
USA

This is a summary of current and emerging pharmacologic therapies utilized in the treatment of diabetic retinopathy (DR). Current therapies, such as ranibizumab, bevacizumab, triamcinolone acetonide, and fluocinolone acetonide, inhibit angiogenesis and inflammation and may be used alone or in combination with laser treatment. Emerging therapies aim to reduce oxidative stress or inhibit other signal transduction pathways, including the protein kinase C cascade and aldose reductase pathway. Future therapies may target other molecules crucial to the pathogenesis of DR, including hepatocyte growth factors and matrix metalloproteinase 9. Finally, the emergence of novel mechanisms of medication delivery may also be on the horizon.


How to cite this article:
Dedania VS, Bakri SJ. Novel pharmacotherapies in diabetic retinopathy.Middle East Afr J Ophthalmol 2015;22:164-173


How to cite this URL:
Dedania VS, Bakri SJ. Novel pharmacotherapies in diabetic retinopathy. Middle East Afr J Ophthalmol [serial online] 2015 [cited 2021 Nov 29 ];22:164-173
Available from: http://www.meajo.org/article.asp?issn=0974-9233;year=2015;volume=22;issue=2;spage=164;epage=173;aulast=Dedania;type=0